Kura Oncology (KURA) Receivables - Net (2024 - 2026)

Kura Oncology (KURA) has 3 years of Receivables - Net data on file, last reported at $9.3 million in Q1 2026.

• Quarterly Receivables - Net fell 80.82% year-over-year to $9.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.3 million (down 80.82% YoY) and the FY2025 annual result came in at $8.8 million, up 327.38% from the prior year.
• Receivables - Net improved to $9.3 million in Q1 2026 per KURA's latest filing, from $8.8 million in the prior quarter.
• Across five years, Receivables - Net topped out at $48.7 million in Q1 2025 and bottomed at $2.1 million in Q4 2024.
• The 3-year median for Receivables - Net is $9.1 million (2025), against an average of $18.2 million.
• The widest annual swing landed in 2025, when Receivables - Net jumped 327.38%; it then slumped 80.82% in 2026.
• Tracing KURA's Receivables - Net over 3 years: stood at $2.1 million in 2024, then jumped by 327.38% to $8.8 million in 2025, then grew by 6.18% to $9.3 million in 2026.
• Per Business Quant, the three latest KURA Receivables - Net figures stand at $9.3 million (Q1 2026), $8.8 million (Q4 2025), and $35.9 million (Q3 2025).

Peer Comparison